Ads
related to: castration resistant prostate cancer cells but no tumor- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Prostate Cancer
Discover Prostate Cancer Treatments
Download our Prostate Cancer Guide
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Second Opinion
Search results
Results from the WOW.Com Content Network
DU145, PC3, and LNCaP are considered to be the standard prostate cancer cell lines used in therapeutic research. [ 1 ] The DU145 cell line was derived from a central nervous system metastasis , of primary prostate adenocarcinoma origin, removed during a parieto-occipital craniotomy of a 69-year-old, White, male.
Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.
Prostate cancer (PC) is the most common form of non-cutaneous malignant cancer in males, and is the second leading cause of cancer deaths in males. [12] PC3 cells have been utilized to research aggressive and castration-resistant forms of pancreatic cancer.
Genetic lineage marking demonstrated that rare luminal cells that express NKX3-1 in the absence of testicular androgens are bipotential and can self-renew in vivo. Single-cell transplantation assays showed that castration-resistant NKX3-1 expressing cells (CARNs) can reconstitute prostate ducts in renal grafts.
Tasquinimod (ABR-215050, CID 54682876) is an experimental drug currently being investigated for the treatment of solid tumors. Tasquinimod has been mostly studied in prostate cancer, but its mechanism of action suggests that it could be used to treat other cancers. Castration-resistant prostate cancer (CRPC), formerly called hormone-resistant ...
EPI-001 inhibits AR-dependent proliferation of human prostate cancer cells while having no significant effects on cells that do not require the AR for growth and survival. [2] EPI-001 has specificity to the AR (aside from the PPARγ) and has excellent anti-tumor activity in vivo with xenografts of CRPC. [2]
Irreversible electroporation (IRE) is an emerging focal therapy for prostate cancer, particularly suitable for small tumors confined to the prostate. Unlike traditional treatments such as radical prostatectomy or radiation therapy, which may lead to side effects like urinary incontinence and erectile dysfunction, IRE aims to minimize such risks ...
Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (AIPC). This stage leads to mCRPC with lymph node involvement and distal (distant) tumors; this is the lethal stage of CaP. The prostate cancer staging designation is T4,N1,M1c. [5] [6] [7]
Ads
related to: castration resistant prostate cancer cells but no tumor